Ocugen Inc Stock Price Target Forecast, (OCGN) Prediction 2022, 2023, 2025, 2030

December 8, 2021

Stock projection for Ocugen (OCGN): A boost or too little, too late?

According to MarketBeat statistics, Wall Street analysts give Ocugen a consensus ‘hold’ rating, with two ‘buy’ ratings, three ‘hold’ ratings, and zero’sell’ ratings. The stock price forecast for Ocugen Inc over the next 12 months ranges from $4.00 to $15, with an average price estimate of $7.90.

This year, Ocugen has been covered by five analysts. In June, Chardan Capital decreased its price objective on Ocugen shares from $8 to $4.50, implying a 37.5 percent drop.

Not all experts, though, are so pessimistic. Following the announcement on October 27 that Ocugen was seeking FDA clearance, Noble Financial’s Robert LeBoyer confirmed his buy recommendation and set a price target of $15, representing a 48.37 percent upside on the day.

In light of Ocugen’s application to initiate FDA clinical trials, Roth Capital and Cantor Fizgerald both restated their ratings on November 2nd, keeping their ‘hold’ and ‘neutral’ ratings, respectively.

It’s important to remember that analyst predictions aren’t always accurate. Forecasts should never be utilised in place of your own study. Before you invest, make sure you do your homework. Also, never trade or invest money you can’t afford to lose.

Long-term outlook for the Ocugen stock (2021-2025)

Wallet Investor’s algorithm-based service believes that the stock price might top $15 by the end of December 2022, despite the fact that analysts seldom make long-term stock projections. The forecasting firm predicts that by the end of the year, the price will have risen to roughly $20.

The estimates from Wallet Investor analyse previous price movements to forecast future prices. It’s important to remember that algorithm-based forecasts are frequently incorrect, and previous success does not guarantee future outcomes. Forecasts should never be utilised in place of your own study. Before you invest, make sure you do your homework. Also, never trade or invest money you can’t afford to lose.

Technical analysis by OCGN

The relative strength index (RSI) for Ocugen is neutral at 37.34, according to TradingView. When the RSI falls below 30, it indicates that the asset is oversold and cheap. Despite the fact that Ocugen shares spent much of 2020 sitting above this level, the present level does not indicate that the company is likely to break out again. Although the RSI reached 70 in late October, it no longer indicates that the Ocugen share price is poised to plummet.

capital.com is the source for this information.


November 3, 2021

Should You Buy Ocugen Inc. (OCGN) on Wednesday Morning?

The shares of Ocugen Inc (OCGN) was down -3.13 percent in pre-market trade on Wednesday morning, closing at 15.18. OCGN’s short-term technical score of 98 shows that the stock has moved more bullishly than 98 percent of other stocks in the market over the last month. The stock ranks higher than 100% of stocks in the Biotechnology industry, which ranks 139 out of 146 industries. Ocugen Inc has increased by 124.50 percent in the last month, ending at $6.80 on October 6th. The price dropped as low as $6.80 and as high as $14.50 throughout this time. The average analyst rating for OCGN is Buy. The average price estimate for the firm is $8.88.

investorsobserver.com is the source for this information.


October 18, 2021.

Ocugen Stock Price and Forecast: Why is OCGN stock dumping?

In December of last year, OCGN shares were trading at $0.30, but by February 2021, they had risen to about $20. Ocugen’s partnership with Bharat Biotech was the catalyst for the stock’s rise. Bharat is a vaccine firm based in India that is attempting to bring its COVAXIN COVID-19 vaccine to market. COVAXIN will be brought to the US market by Ocugen, which will handle regulatory approval and distribution. On April 22, OCGN soared once again when positive trial data for the COVAXIN medication was announced.

OCGN shares failed to break beyond prior highs set in February, but they still managed to rise 42 percent on the day. On May 3, more increases were detected when Ocugen stated that COVAXIN is effective against the COVID-19 virus’s primary forms. Since then, the stock has been pretty peaceful, and it wasn’t until last week that interest resurfaced, when social media caught wind of the stock and interest skyrocketed.

Stock prediction for Ocugen (OCGN)

We remain wary on this one and recommend that you trade with caution and good risk management. This news appears to be beneficial, but just for the Indian market. Ocugen is based in the United States. A powerful advance like this one, from a technical standpoint, requires consolidation rather than a drop back to where it began if it is to continue. Ocugen is also in a high volume zone, which means it has to breach $11 and close above it to truly start moving. At $6.50, there is a large volume shelf, so keep a watch on the stock if it begins to trade below that level, as it may accelerate. In our opinion, the stock’s failure to break over the prior spike high of $11 is also negative. This is a classic spike stock, with each spike lower than the one before it, indicating a negative trend.

fxstreet.com is the source for this information.


April 29, 2021

Ocugen, Inc. (NASDAQ:OCGN) is 46 percent undervalued, according to an intrainsic calculation.

Today, we’ll walk over a simple valuation technique for estimating the attractiveness of Ocugen, Inc. (NASDAQ:OCGN) as an investment opportunity, which involves taking the company’s projected future cash flows and discounting them back to today’s value. On this time, we’ll employ the Discounted Cash Flow (DCF) model. Just on reading if you believe you won’t be able to grasp it. It’s not quite as complicated as you may think.

We use a two-stage growth model, which basically means we consider two stages of a company’s development. The company’s growth rate may be higher in the beginning, but it is commonly expected to be stable in the second stage. In the first step, we must forecast the business’s cash flows for the following ten years. We utilise analyst estimates wherever feasible, but if none are available, we extrapolate the historical free cash flow (FCF) from the most recent estimate or reported number. Over this period, we expect firms with falling free cash flow to moderate their shrinkage, and those with expanding free cash flow to delay their growth. This is to represent the fact that growth slows down more in the early years than it does later in life.

To arrive at a present value estimate, we discount the sum of these future cash flows, assuming that a dollar today is more valuable than a dollar in the future.

nasdaq.com is the source for this information.


April 8, 2021

Why Has Ocugen’s Stock Outperformed Its Fundamentals?

Ocugen is a biopharmaceutical business specialising in the discovery, development, and commercialization of treatments for disorders that cause blindness. The business has recently received international notice for its collaboration with an Indian partner on the COVID-19 vaccine COVAXIN. Is it a buy or a sell based on Ocugen’s (OCGN) stock forecast? The approval of COVAXIN’s usage in the United States, which is unlikely, might be one of the primary catalysts for Ocugen stock.

Stock outlook for OCGN

According to Market Beat, Ocugen is currently covered by four analysts. The stock currently has three buy recommendations and one hold rating. The average price objective for the company is $4.8, implying a nearly 30% downside potential.

Roth Capital raised its target price for OCGN from $9 to $10 on March 4.

The EUA in India, according to Roth Capital analyst Zegbeh Jallah, raises the likelihood of the FDA giving COVAXIN the EUA.

marketrealist.com is the source for this information.


Disclaimer: The views and investment tips expressed by investment expert on Stock consultant bihar are Sourced From Brokerage Firms Research Reports & Market Experts Opinion. We advises users to consult your investment advisor before taking any decisions. Our Website Contain Demat Account & Algo Trading affliate Link. If You’ll Register Through Our Link We May Get Profit.

More US Stocks Forecast Updates:

 

We will be happy to hear your thoughts

Leave a reply

Stock Consultant Bihar
Logo